import { DiscoveryCard } from '../types';

export const SEED_DISCOVERIES: DiscoveryCard[] = [
  {
    id: "lenacapavir-prep-2024",
    title: "Lenacapavir 100% Efficacy in PURPOSE 1 Trial",
    country_or_region: "Global / South Africa & Uganda",
    discovery_type: "Clinical Trial",
    summary: "Twice-yearly injectable lenacapavir demonstrated 100% efficacy for HIV prevention in cisgender women, with zero infections recorded in the treatment arm.",
    why_this_matters: "Provides a highly effective, long-acting prevention option that only requires two doses per year, potentially solving adherence challenges.",
    date_announced: "June 2024",
    sources: ["Gilead Sciences", "NEJM", "PURPOSE 1 Study Group"],
    confidence_basis: "Phase 3 double-blind clinical trial results"
  },
  {
    id: "namibia-95-95-95-2024",
    title: "Namibia Reaches 95-95-95 Targets",
    country_or_region: "Namibia",
    discovery_type: "Public Health Impact",
    summary: "Namibia has become one of the first countries in sub-Saharan Africa to achieve the UNAIDS 95-95-95 targets, ensuring widespread diagnosis and suppression.",
    why_this_matters: "Demonstrates that epidemic control is possible in high-burden settings through sustained political commitment and decentralized care.",
    date_announced: "August 2024",
    sources: ["UNAIDS", "Ministry of Health (Namibia)", "PEPFAR"],
    confidence_basis: "National surveillance data and UNAIDS validation"
  },
  {
    id: "who-cab-la-guideline-2025",
    title: "WHO Expands Long-Acting PrEP Implementation Guidelines",
    country_or_region: "Global",
    discovery_type: "Policy",
    summary: "The WHO released updated guidelines for the rapid scale-up of long-acting injectable cabotegravir (CAB-LA), prioritizing key populations and high-incidence areas.",
    why_this_matters: "Streamlines the regulatory and implementation pathways for countries to introduce next-generation prevention tools.",
    date_announced: "January 2025",
    sources: ["WHO", "IAS 2025 Pre-conference Report"],
    confidence_basis: "World Health Organization Guideline Update"
  },
  {
    id: "doxy-pep-std-prevention-2024",
    title: "Doxy-PEP Implementation for HIV-Positive Individuals",
    country_or_region: "United States",
    discovery_type: "Implementation",
    summary: "CDC released clinical guidelines for Doxy-PEP (post-exposure doxycycline) to prevent bacterial STIs among MSM and transgender women living with or at risk for HIV.",
    why_this_matters: "Reducing the burden of co-occurring STIs directly improves health outcomes and reduces biological factors that can increase HIV transmission risk.",
    date_announced: "June 2024",
    sources: ["CDC", "MMWR Reports"],
    confidence_basis: "Official CDC Clinical Guidelines"
  },
  {
    id: "gene-editing-ehv-2026",
    title: "EBT-101 CRISPR Phase 1/2 Preliminary Safety Results",
    country_or_region: "United States",
    discovery_type: "Research",
    summary: "Excision BioTherapeutics reported safe delivery and preliminary excision data for EBT-101, a CRISPR-based therapy designed to remove HIV proviral DNA from the genome.",
    why_this_matters: "A critical step toward a scalable 'excisional' cure that targets the hidden viral reservoir in living cells.",
    date_announced: "Expected Early 2026",
    sources: ["Excision BioTherapeutics", "ClinicalTrials.gov (NCT05144386)"],
    confidence_basis: "Ongoing Phase 1/2 Clinical Trial"
  },
  {
    id: "islatravir-combination-2025",
    title: "Islatravir/Lenacapavir Oral Combination Success",
    country_or_region: "Global",
    discovery_type: "Clinical Trial",
    summary: "Phase 2 results for once-weekly oral islatravir and lenacapavir showed sustained viral suppression equivalent to daily Biktarvy.",
    why_this_matters: "Moves treatment toward weekly rather than daily dosing, reducing pill fatigue and improving long-term adherence options.",
    date_announced: "March 2025",
    sources: ["Merck & Co.", "Gilead Sciences", "CROI 2025"],
    confidence_basis: "Peer-reviewed Phase 2 trial results"
  },
  {
    id: "brazil-prep-expansion-2024",
    title: "Brazil Surpasses 100,000 PrEP Users",
    country_or_region: "Brazil",
    discovery_type: "Implementation",
    summary: "Brazil's SUS reached a milestone of over 100,000 active PrEP users, significantly scaling access through basic health units and pharmacies.",
    why_this_matters: "Proof-of-concept for a nationalized, free-of-charge prevention program in a middle-income country with a diverse epidemic.",
    date_announced: "December 2024",
    sources: ["Ministry of Health (Brazil)", "SVS/MS"],
    confidence_basis: "Government health management system (SIS PREP)"
  },
  {
    id: "bna-antibodies-2026",
    title: "Broadly Neutralizing Antibodies (bNAbs) for Prevention",
    country_or_region: "Global",
    discovery_type: "Research",
    summary: "Combinations of three broadly neutralizing antibodies (bNAbs) showed superior protection against a wider range of HIV variants in high-risk cohorts.",
    why_this_matters: "Paves the way for passive immunization strategies that could last 6-12 months per administration.",
    date_announced: "Projected Mid-2026",
    sources: ["HVTN", "IAVI", "NIH Vaccine Research Center"],
    confidence_basis: "Early-phase laboratory and animal model efficacy data"
  }
];
